Irradiation of stage I and II Hodgkin's disease.
Irradiation of stage I and II Hodgkin's disease.
复制标题
I 期和 II 期霍奇金病的照射。
DOI：
10.2214/ajr.123.1.154
复制
发表时间：
1975
期刊：
影响因子：
--
通讯作者：
W. Turner
中科院分区：
文献类型：
--
作者：
J. Fazekas;J. Cox;W. Turner
必须根据上述分析得出结论，超过3,600或4,000拉德的肿瘤剂量只会增加发病率，而不会增加局部控制。其次，仅照射受累淋巴结组，而将其他区域留待“以后”治疗的技术，显然否定了相当多的早期霍奇金氏病患者治愈的可能性。复发或延长几乎一致地导致最终死于疾病，尽管再次治疗。在本报告中包括的患者群体中没有第二原发癌病例的记录。然而，面临风险的人数相对较少，化疗仅适用于全身复发。由于报告的20倍预期发病率发生在全结节化疗和多药化疗的组合中，因此在本系列中，第二原发灶的发病率不会增加。
One must conclude on the basis of the above analysis that tumor doses in excess of 3,600 or 4,000 rads add only to morbidity, and not to local control. Secondly, the technique of irradiating involved lymph node groups only, leaving other areas to be treated "later," apparently denies the possibility of cure to a significant number of patients with early stage Hodgkin's disease. Recurrence or extension almost uniformly leads to eventual death from disease despite retreatment. No case of second primary cancer has been documented in the patient population included in this report. However, the number at risk is relatively small and chemotherapy was reserved only for generalized recurrence. Since the reported 20 times expected incidence occurred with the combination of total-nodal and multple-agent chemotherapy, one would not expect an increased incidence of second primary lesions in this series.
影响因子：
11.2
作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
通讯作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana